Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | STK4 | Q13043 | 2/20 | 0.33 |
| ▸ | STK3 | Q13188 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917542 | 0.77 | PIK3CD (0.45) | RETPIK3CDPIK3CGMET | |
| SCHEMBL23917468 | 0.72 | RET (0.57) | RETPIK3CDPIK3CGLRRK2FLT3 | |
| SCHEMBL16665728 | 0.72 | RET (0.56) | RET | |
| SCHEMBL16655896 | 0.69 | PIK3CD (0.49) | RETPIK3CDFLT3MET | |
| SCHEMBL16665717 | 0.68 | RET (0.33) | RETPIK3CDPIK3CGLRRK2STK4 | |
| SCHEMBL4352960 | 0.67 | LRRK2 (0.58) | RETLRRK2FLT3STK4STK3 | |
| SCHEMBL16655726 | 0.67 | PIK3CD (0.52) | RETPIK3CDFLT3MET | |
| SCHEMBL4353306 | 0.66 | LRRK2 (0.62) | LRRK2STK4STK3 | |
| SCHEMBL6531144 | 0.65 | RET (0.42) | RETLRRK2FLT3STK4STK3 | |
| SCHEMBL30052782 | 0.65 | RET (0.42) | RETLRRK2FLT3STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | RET 753/4885PIK3CD 2/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.